257 related articles for article (PubMed ID: 33471733)
1. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
Tezuka Y; Turcu AF
Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
[TBL] [Abstract][Full Text] [Related]
2. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
[TBL] [Abstract][Full Text] [Related]
3. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
Browne GA; Griffin TP; O'Shea PM; Dennedy MC
Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
[TBL] [Abstract][Full Text] [Related]
4. Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone-renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design.
Rossitto G; Cesari M; Ceolotto G; Maiolino G; Seccia TM; Rossi GP
J Hum Hypertens; 2019 Feb; 33(2):167-171. PubMed ID: 30518805
[TBL] [Abstract][Full Text] [Related]
5. Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
Tezuka Y; Turcu AF
Front Endocrinol (Lausanne); 2021; 12():625457. PubMed ID: 33841329
[TBL] [Abstract][Full Text] [Related]
6. Subtype Identification of Surgically Curable Primary Aldosteronism During Treatment With Mineralocorticoid Receptor Blockade.
Pintus G; Seccia TM; Amar L; Azizi M; Riester A; Reincke M; Widimský J; Naruse M; Kocjan T; Negro A; Kline G; Tanabe A; Satoh F; Rump LC; Vonend O; Fuller PJ; Yang J; Chee NYN; Magill SB; Shafigullina Z; Quinkler M; Oliveras A; Lee BC; Chang CC; Wu VC; Krátká Z; Battistel M; Bagordo D; Caroccia B; Ceolotto G; Rossitto G; Rossi GP
Hypertension; 2024 Jun; 81(6):1391-1399. PubMed ID: 38525605
[TBL] [Abstract][Full Text] [Related]
7. Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism.
Nanba AT; Wannachalee T; Shields JJ; Byrd JB; Rainey WE; Auchus RJ; Turcu AF
J Clin Endocrinol Metab; 2019 Feb; 104(2):487-492. PubMed ID: 30239792
[TBL] [Abstract][Full Text] [Related]
8. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
Parra Ramírez P; Martín Rojas-Marcos P; Paja Fano M; González-Boillos M; Pascual-Corrales E; García Cano AM; Ruiz-Sanchez JG; Vicente Delgado A; Gómez Hoyos E; Ferreira R; García Sanz I; Recasens Sala M; Barahona San Millan R; Picón César MJ; Díaz Guardiola P; Perdomo CM; Manjón-Miguélez L; Rebollo Román Á; Robles Lázaro C; Morales-Ruiz M; Calatayud M; Andree Furio Collao S; Meneses D; Sampedro-Nuñez MA; Mena Ribas E; Sanmartín Sánchez A; Gonzalvo Diaz C; Lamas C; Guerrero-Vázquez R; Del Castillo Tous M; Serrano Gotarredona J; Michalopoulou Alevras T; Tenés Rodrigo S; Roa Chamorro R; Jaen Aguila F; Moya Mateo EM; Hanzu FA; Araujo-Castro M
High Blood Press Cardiovasc Prev; 2024 Jan; 31(1):43-53. PubMed ID: 38225508
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone, Renin, and Aldosterone-to-Renin Ratio Variability in Screening for Primary Aldosteronism.
Ng E; Gwini SM; Libianto R; Choy KW; Lu ZX; Shen J; Doery JCG; Fuller PJ; Yang J
J Clin Endocrinol Metab; 2022 Dec; 108(1):33-41. PubMed ID: 36179243
[TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
[TBL] [Abstract][Full Text] [Related]
11. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
[TBL] [Abstract][Full Text] [Related]
12. Impact of the withdrawal of renin-angiotensin-aldosterone inhibitors on mortality in COVID-19 patients.
Caro-Codón J; Rey JR; Iniesta AM; Rosillo SO; Castrejon-Castrejon S; Rodriguez-Sotelo L; Garcia-Veas JM; Marco I; Martinez LA; Martin-Polo L; Merino C; Martinez-Cossiani M; Buño A; Gonzalez-Valle L; Herrero A; López-de-Sá E; Merino JL;
Rev Port Cardiol; 2022 Oct; 41(10):823-830. PubMed ID: 35784098
[TBL] [Abstract][Full Text] [Related]
13. Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data.
Pilz S; Trummer C; Verheyen N; Schwetz V; Pandis M; Aberer F; Grübler MR; Meinitzer A; Bachmann A; Voelkl J; Alesutan I; Catena C; Sechi LA; März W; Obermayer-Pietsch B; Tomaschitz A
Horm Metab Res; 2018 May; 50(5):375-382. PubMed ID: 29723896
[TBL] [Abstract][Full Text] [Related]
14. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
15. Practical recommendations for antihypertensive therapy during the primary aldosteronism screening test.
Li J; Yan H; Li L; Lin X; Zhao Z; Zhou C; Zhang Q
Endocrine; 2024 Jan; 83(1):188-195. PubMed ID: 37924464
[TBL] [Abstract][Full Text] [Related]
16. Effects of Ramipril on the Aldosterone/Renin Ratio and the Aldosterone/Angiotensin II Ratio in Patients With Primary Aldosteronism.
Guo Z; Poglitsch M; Cowley D; Domenig O; McWhinney BC; Ungerer JPJ; Wolley M; Stowasser M
Hypertension; 2020 Aug; 76(2):488-496. PubMed ID: 32507039
[TBL] [Abstract][Full Text] [Related]
17. Adrenal Vein Sampling Without Discontinuation of Mineralocorticoid Receptor Antagonist Therapy.
Ganesh M; Abadin SS; Fogelfeld L
Endocr Pract; 2020 Sep; 26(9):953-959. PubMed ID: 33471699
[TBL] [Abstract][Full Text] [Related]
18. Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report.
Brinkley DM; Wang L; Yu C; Grandin EW; Kiernan MS
J Heart Lung Transplant; 2021 Dec; 40(12):1605-1613. PubMed ID: 34663529
[TBL] [Abstract][Full Text] [Related]
19. Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary Aldosteronism.
Guo Z; Poglitsch M; McWhinney BC; Ungerer JPJ; Ahmed AH; Gordon RD; Wolley M; Stowasser M
Clin Chem; 2020 Mar; 66(3):483-492. PubMed ID: 32068832
[TBL] [Abstract][Full Text] [Related]
20. PREVELENCE OF PRIMARY ALDOSTERONISM IN AN URBAN HYPERTENSIVE POPULATION.
Galati SJ; Cheesman KC; Springer-Miller R; Hopkins SM; Krakoff L; Bagiella E; Zhuk RA; Ying TK; Amer C; Boyajian MK; Inabnet WB; Levine AC
Endocr Pract; 2016 Nov; 22(11):1296-1302. PubMed ID: 27893293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
